



# Biotech Daily

Thursday April 13, 2023

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH UP: PROTEOMICS UP 10%; PARADIGM DOWN 5%**
- \* **IMRICOR READY FOR EU NORTHSTAR ICMR TACHYCARDIA TRIAL**
- \* **MICROBA: SNYLAB CENTRAL EUROPE GUT TEST DISTRIBUTORS**
- \* **4D MEDICAL: 'MIAMI UNI LUNG X-RAY DEAL WORTH UP-TO \$1.5m'**
- \* **VITURA REJECTS DR CHARLIE JANSEN EGM CALL**
- \* **PHARMAUST: CEO WANTED**
- \* **4D APPOINTS PROF DAVID SHULKIN ADVISOR**

## MARKET REPORT

The Australian stock market fell 0.27 percent on Thursday April 13, 2023, with the ASX200 down 19.8 points to 7,324.1 points.

Nineteen of the Biotech Daily Top 40 stocks were up, nine fell, nine traded unchanged and three were untraded.

Proteomics was the best, up nine cents or 10 percent to 99 cents, with 215,026 shares traded; followed by Emvision up 14.5 cents or 9.9 percent to \$1.615, with 92,227 shares traded.

Actinogen climbed 6.45 percent; Nova Eye was up 5.6 percent; Imugene improved 3.85 percent; Atomo, Cyclopharm, Dimerix, Genetic Signatures, Immuteq, Next Science, Pharmaxis and Polynovo rose more than two percent; Clinuvel, Nanosonics and Neuren were up more than one percent; with Cochlear, Pro Medicus, Telix and Volpara up by less than one percent.

Paradigm led the falls, down 5.5 cents or 4.8 percent to \$1.095, with 1.2 million shares traded.

Alcidion, Cynata and Oncosil fell more than four percent; Amplia and Mesoblast were down three percent or more; Medical Developments shed 2.3 percent; Starpharma was down 10.5 percent; with Avita, CSL and Resmed down by less than one percent.

## IMRICOR MEDICAL SYSTEMS

Imricor says it has completed the design, testing, and documentation of its Northstar 3D mapping system, allowed it to be added to its European ventricular tachycardia trial. Last year, Imricor said it had filed for European approval of its 64-patient, invasive cardiovascular magnetic resonance-guided (ICMR) ventricular tachycardia ablation clinical trial, titled 'Vision-MR Ablation of VT' or Visabl-VT (BD: Sep 19, Dec 15, 2022).

At that time, the company said the prospective, single-arm, multi-centre trial would investigate the safety and efficacy of radio-frequency ablation of ventricular tachycardia associated with ischemic cardio-myopathy using its Vision-MR ablation catheter 2.0. Imricor said the Northstar-MR used Siemens magnetic resonance imaging (MRI) scanners and removed the reliance on others to develop 3D mapping systems for complex ablation. Today, the company said it had added the Northstar 3D mapping system to the Visabl-VT study protocol and submitted it for approval to start the study at the Hague, Netherlands-based Haga Hospital, with the final approval a review by the hospital's ethics committee, scheduled for May 2, 2023.

Imricor said that Northstar was required for the trial because the Haga ICMR laboratory was based on the Siemens magnetic resonance imaging (MRI) platform and Northstar was "the only 3D mapping system that operates with Siemens MRI systems".

Imricor executive chair Steve Wedan said the company had worked efficiently to complete Northstar's development and to add it to the Visabl-VT study protocol, so sites with Siemens MRI systems could participate in the trial.

"As we expected, the study approval process in the Netherlands is moving more quickly than the process in Germany," Mr Wedan said.

"Recall that we submitted for approval to commence Visabl-VT at the Leipzig Heart Centre in Germany last September," Mr Wedan said.

"We were able to apply earlier, there, because the Leipzig Heart Centre's ICMR lab is based around the Philips MRI platform which currently utilizes Philips' existing Isuite mapping system," Mr Wedan said.

"Our urgency around Northstar's completion was driven by our desire to expand the Visabl-VT study to include sites, like Haga Hospital, that have Siemens ICMR labs and to expand the study to other countries," Mr Wedan said.

"Ultimately, we expect that Northstar will be the 3D mapping system used on other MRI platforms as well, including those from Philips and GE Healthcare," Mr Wedan said.

Imricor said that 28 procedures were performed in the three months to March 31 2023 twice as many as in the previous three months, "it the highest volume quarter in the company's history".

Mr Wedan said that issues of magnetic resonance imaging (MRI) availability at sites where the MRI was a shared resource between departments continued to be an issue, and fewer patients were "presenting to their doctors with standalone atrial flutter compared to pre-pandemic times, we are nonetheless seeing an uptick in procedures volumes, and we hope to continue the trend as more sites become active and engaged".

"Notably, the Amsterdam University Medical Centre performed three ICMR ablation procedures in one day last week," Mr Wedan said.

"We are still in the early stages of our commercial relaunch following the pandemic, and we will continue to focus on developing an installed base of cardiology-owned ICMR labs to drive consistent and sustained growth into the future," Mr Wedan said.

"The upcoming availability of Northstar and the anticipation around the Visabl-VT trial is helping to generate renewed excitement in the field, and we are beginning to regain the momentum we had in early 2020," Mr Wedan said.

Imricor was up half a cent or 1.7 cents to 30 cents.

## MICROBA LIFE SCIENCES

Microba says Synlab International GmbH subsidiaries will distribute its gut microbiome tests in Poland, Hungary, Romania and Croatia.

Last year, Microba said it would extend and expand its agreement with the Munich-based Synlab for the distribution of its microbiome tests in Europe (BD: Oct 20, 2022).

Today, the company said the new agreements brought the number of distribution agreements to nine, including Spain, Italy, Portugal, Turkey and the Czech Republic. Microba was unchanged at 31.5 cents.

## 4D MEDICAL

4D Medical says the Coral Gables, Florida-based University of Miami will pay a minimum fee in the range of \$1 million to \$1.5 million for its XV LVAS contract.

Last week, 4D said it had its first software-as-service contract to provide University of Miami with its XV LVAS x-ray velocimetry lung ventilation analysis software but did not disclose the value of the five-year contract (BD: Apr 5, 2023).

Today, the company said the minimum fees provided the University of Miami with defined volumes and types of scans, with the company to earn additional fees for additional scans beyond the minimum fees, with the minimum fees not repayable in the event of early termination by the University of Miami.

4D Medical was up two cents or 2.7 cents to 76.5 cents with 3.6 million shares traded.

## VITURA HEALTH (FORMERLY CRONOS AUSTRALIA)

Vitura says it has rejected a general meeting call from Cannabis Doctors Australia founder Dr Matua Hasyo Charlie Jansen as trustee for the Whanau Family Trust.

Vitura said Dr Jansen had requested the directors provide a one-cent, fully-franked interim dividend to shareholders, but said the resolution could not be effected by shareholders in a general meeting.

The company said that “the declaration and payment of dividends ... [was] within the exclusive powers of the company's directors”.

Last September, the then Cronos Australia said Dr Charlie Jansen, as trustee for the Whanau Family Trust, had called for the removal of director and chief executive officer Rodney Cocks and director and chief commercial officer Guy Headley at its next annual general meeting (BD: Sep 20, 2022).

In November, the company said the board-opposed resolutions to remove Mr Cocks and Mr Heady were defeated with up-to 88 percent opposition (BD: Nov 29, 2022).

According to Vitura's 2022 annual report, Dr Charlie Jansen owned 55,076,378 shares, or 9.93 percent of the company and a one cent dividend would equate to \$550,764.

Vitura was unchanged at 34.5 cents.

## PHARMAUST

Pharmaust says it has begun a search for a new Australia-based chief executive officer. Pharmaust said it was seeking a person with “strong knowledge in [US Food and Drug Administration] certification and global licencing agreements”.

The company said the chief executive officer would “display proven abilities in regular contact and communication with the investment community”.

Pharmaust said that executive chair Dr Roger Aston would transition to non-executive.

Pharmaust was up 0.6 cents or 6.1 cents to 10.5 cents.

## 4D MEDICAL

4D Medical says it has appointed Prof David Shulkin as an advisor.

4D Medical said Prof Shulkin was formerly the Secretary of the US Department of Veterans Affairs, overseeing more than 350,000 employees, 1,700 facilities for more than nine million US veterans.

The company said that previously Prof Shulkin had been New York's Beth Israel Medical Centre chief executive officer, the West Philadelphia-based University of Pennsylvania Hospital's first chief medical officer, Philadelphia's Drexel College of Medicine's chair of medicine and New York's Albert Einstein College of Medicine's professor of medicine. Prof Shulkin's LinkedIn page said that he held a Doctor of Medicine from the University of Pennsylvania.